Gaps and Opportunities to Improve Prevention of Human Papillomavirus-related Cancers

The Society for Women’s Health Research (SWHR) published a paper in the Journal of Women’s Health, capturing the current landscape of HPV-related anogenital cancers, their effects on women’s health, and recommended areas in which to address gaps in primary and secondary prevention approaches to improve access and health outcomes for women. These insights were collected from a series of interdisciplinary meetings and events with expert researchers, clinicians, patient advocates, and health care policy leaders, convened by SWHR. 

Human papillomavirus (HPV) infections cause more than 35,900 cancers annually in the United States, with cervical cancer being the most prevalent HPV-related malignancy in women. While a comprehensive approach to mitigating cervical cancer includes HPV vaccination (primary prevention), screening and treatment of precancerous lesions (secondary prevention), and diagnosis and treatment of invasive cancer (tertiary prevention), there are still opportunities to innovate and increase access that can also be adapted to address the unique clinical care gaps that exist with the other anogenital cancers. 

READ THE FULL PAPER HERE

The Society for Women’s Health Research (SWHR) published a paper in the Journal of Women’s Health, capturing the current landscape of HPV-related anogenital cancers, their effects on women’s health, and recommended areas in which to address gaps in primary and secondary prevention approaches to improve access and health outcomes for women. These insights were collected from a series of interdisciplinary meetings and events with expert researchers, clinicians, patient advocates, and health care policy leaders, convened by SWHR. 

Human papillomavirus (HPV) infections cause more than 35,900 cancers annually in the United States, with cervical cancer being the most prevalent HPV-related malignancy in women. While a comprehensive approach to mitigating cervical cancer includes HPV vaccination (primary prevention), screening and treatment of precancerous lesions (secondary prevention), and diagnosis and treatment of invasive cancer (tertiary prevention), there are still opportunities to innovate and increase access that can also be adapted to address the unique clinical care gaps that exist with the other anogenital cancers. 

READ THE FULL PAPER HERE

More from SWHR about HPV

Blog Post
New Paper Sheds Light on HPV-Related Cancers Landscape
By Monica Lefton, SWHR Communications Manager. Human papillomavirus (HPV) infections cause more than 35,900 cancers annually in the United States, and cervical cancer is the most prevalent HPV-related malignancy in women. Recent studies show the United States lags behind other developed countries like the United Kingdom when it comes to HPV vaccination and subsequent cervical cancer incidence rates. While cervical cancer... Read more »
Event
Opportunities for Innovation in HPV-Related Disease
SWHR hosted a virtual public forum on the need for innovation in HPV-related disease screening and treatment for women.
November 12, 2020 @ 2:00 pm - 3:15 pm EST
Blog Post
Pandemic Imperils Cancer Prevention, Screening, and Treatment for Women
Many women have been hesitant or unable to attend health care visits because of the COVID-19 pandemic, leading to thousands of missed annual wellness visits, vaccinations, and cancer screenings.

This program was supported by an educational sponsorship from Inovio. SWHR maintains editorial control and independence over educational content.